Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Market Cap	3.33B
Revenue (ttm)	159.02M
Net Income (ttm)	19.25M
Shares Out	51.21M
EPS (ttm)	0.41
PE Ratio	158.58
Forward PE	n/a
Dividend	0.09 (0.14%)
Ex-Dividend Date	Aug 25, 2025

Volume	80,475
Average Volume	102,816
Open	66.80
Previous Close	67.20
Day's Range	66.10 - 67.30
52-Week Range	39.32 - 91.20
Beta	n/a
RSI	36.07
Earnings Date	Nov 13, 2025

About Pet Pharm Biotech

Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7762

Financial Performance

In 2024, Pet Pharm Biotech's revenue was 130.70 million, an increase of 10.89% compared to the previous year's 117.87 million. Earnings were 14.51 million, an increase of 58.54%.